Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy

Journal of the Formosan Medical Association

Volumn 110, Issue 6, 2011, Pages 363-371

  Kuo, Yuan Hung ^a   Chuang, Tang Wei ^b   Hung, Chao Hung ^a   Chen, Chien Hung ^a   Wang, Jing Houng ^a   Hu, Tsung Hui ^a   Lu, Sheng Nan ^a   Lee, Chuan Mo ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Cholesterol (TC); Hepatitis C virus; Peginterferon; Reversal; Triglyceride

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFECT; ERADICATION THERAPY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HYPOCHOLESTEROLEMIA; HYPOLIPEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79960378665     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(11)60054-5     Document Type: Article

References (37)

1. Seeff LB. Natural history of hepatitis C. Hepatology 2002; 36:S35-46.
2. Lee CM, Hung CH, Lu SN, et al. Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan. Intervirology 2006;49:76-81.
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
4. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995;123:615-20.
5. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 1997;4: 9-28.
6. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-33.
7. Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol 2007;102: 1237-43.
8. Fartoux L, Poujol-Robert A, Guechot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;54:1003-8.
9. Serfaty L, Andreani T, Giral P, et al. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001;34:428-34.
10. Hung CH, Lee CM, Chen CH, et al. Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. Liver Int 2009;29:1086-93.
11. Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 2008;49: 9-16.
12. Andre P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density hepatitis C virus RNAcontaining particles. J Virol 2002;76:6919-28.
13. Thomssen R, Bonk S, Propfe C, et al. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 1992;181:293-300.
14. Monazahian M, Kippenberger S, Muller A, et al. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol Immunol (Berl) 2000;188:177-84.
15. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002;16:185-94.
16. Hsu CS, Liu CJ, Liu CH, et al. Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol Int 2008;2:250-7.
17. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
18. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
19. Gopal K, Johnson TC, Gopal S, et al. Correlation between lipid profile and outcome of hepatitis C treatment. Hepatology 2006;44:335-40.
20. Toyoda H, Kumada T. Cholesterol and lipoprotein levels as predictors of response to interferon for hepatitis C. Ann Intern Med 2000;133:921.
21. Hung CH, Kuo FY, Wang JH, et al. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antivir Ther 2006;11:483-9.
22. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-90.
23. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
24. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
25. Regulations for NHI medical care. Taipei, Bureau of National Health Insurance, Republic of China, 2005.
26. Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96: 12766-71.
27. André P, Perlemuter G, Budkowska A, et al. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis 2005;25:93-104.
28. Corey KE, Kane E, Munroe C, et al. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009;50:1030-7.
29. Hamamoto S, Uchida Y, Wada T, et al. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol 2005;20:204-8.
30. Tada S, Saito H, Ebinuma H, et al. Treatment of hepatitis c virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism. Hepatol Res 2009; 39:195-9.
31. Shinohara E, Yamashita S, Kihara S, et al. Interferon alpha induces disorder of lipid metabolism by lowering post heparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 1997;25: 1502-6.
32. Grunfeld C, Dinarello CA, Feingold KR. Tumor necrosis factor-α, interleukin-1, and interferon alpha stimulate triglyceride synthesis in HepG2 cells. Metabolism 1991;40: 894-8.
33. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype J Hepatol 2000;33:106-15.
34. Hezode C, Roudot-Thoraval F, Zafrani ES, et al. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004;11:455-8.
35. Fernández-Rodríguez CM, López-Serrano P, Alonso S, et al. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 2006; 24:507-12.
36. Hsu CS, Liu CH, Liu CJ, et al. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol 2009; 104:598-604.
37. Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005;12: 283-91.